United States Food and Drug Administration (USFDA) has approved United States-based Merck's anti-PD-1 therapy Keytruda (pembrolizumab) intended for treatment of head and neck cancer, it was reported yesterday.
The regulator has approved the product as monotherapy and in combination with chemotherapy regimen platinum and fluorouracil. The approval is for first-line treatment of metastatic or with unresectable, recurrent head and neck squamous cell carcinoma as monotherapy in patients whose tumours express the biomarker PD-L1.
The drug's approval in combination with fluorouracil is for the treatment of the same condition, irrespective of PD-L1 expression.
The product received extended approval as a result of the findings of a phase three KEYNOTE-048 trial in which the product significantly improved overall survival in comparison to the EXTREME regimen (cetuximab with carboplatin or cisplatin plus fluorouracil). This was showcased with the drug used as monotherapy and in combination with chemotherapy.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study